Matching articles for "November 17"

Correction: Bendamustine (Treanda) for CLL and NHL

   
The Medical Letter on Drugs and Therapeutics • December 1, 2008;  (Issue 1300)
(Med Lett Drugs Ther 2008; 50:91) In the Clinical Studies section, the complete response rate with chlorambucil for CLL was 2% (not...
(Med Lett Drugs Ther 2008; 50:91) In the Clinical Studies section, the complete response rate with chlorambucil for CLL was 2% (not 24%).
Med Lett Drugs Ther. 2008 Dec 1;50(1300):96 | Show Full IntroductionHide Full Introduction

Advertisements for TNF Inhibitors

   
The Medical Letter on Drugs and Therapeutics • November 17, 2008;  (Issue 1299)
Some tumor necrosis factor (TNF) inhibitors are being promoted on the internet directly to the public for use in psoriasis...
Some tumor necrosis factor (TNF) inhibitors are being promoted on the internet directly to the public for use in psoriasis (www.yahoo.com).
Med Lett Drugs Ther. 2008 Nov 17;50(1299):89 | Show Full IntroductionHide Full Introduction

Safety of SSRIs in Pregnancy

   
The Medical Letter on Drugs and Therapeutics • November 17, 2008;  (Issue 1299)
Depression occurs in up to 20% of pregnant women, and the use of selective serotonin reuptake inhibitors (SSRIs) in these women has been increasing. Maternal depression has itself been associated with...
Depression occurs in up to 20% of pregnant women, and the use of selective serotonin reuptake inhibitors (SSRIs) in these women has been increasing. Maternal depression has itself been associated with intrauterine growth problems and low birth weight, so the risks of exposure to antidepressants during pregnancy must be weighed against the risks of untreated depression, which also include self-harm, poor bonding and poor parenting. SSRIs available in the US for treatment of depression include citalopram (Celexa, and others), escitalopram (Lexapro), fluoxetine (Prozac, and others), paroxetine (Paxil, and others) and sertraline (Zoloft).

Click here to view the free full article.
Med Lett Drugs Ther. 2008 Nov 17;50(1299):89-91 | Show Full IntroductionHide Full Introduction

Bendamustine (Treanda) for CLL and NHL

   
The Medical Letter on Drugs and Therapeutics • November 17, 2008;  (Issue 1299)
Bendamustine HCl (Treanda - Cephalon), an unusual DNA-alkylating agent that has been used in Europe for many years to treat lymphoma, has now been approved by the FDA for treatment of chronic lymphocytic...
Bendamustine HCl (Treanda - Cephalon), an unusual DNA-alkylating agent that has been used in Europe for many years to treat lymphoma, has now been approved by the FDA for treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL).
Med Lett Drugs Ther. 2008 Nov 17;50(1299):91-2 | Show Full IntroductionHide Full Introduction